Danaher Corporation (DHR)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $163.94B
Last updated: Nov 17, 2026 at 11:04 AM ET
Danaher Corporation (DHR) Stock Forecast
Analysts expect Danaher (DHR) to earn $8.59 per share in the fiscal year ending Dec 31, 2026, on revenue of $26.26B. Of 24 analysts, 20 rate the stock Buy or Strong Buy, 4 Hold and 0 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 23 estimates for the fiscal year ending Dec 31, 2026 were revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 24 ratings average 2.04, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 83% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 3 | 12.5% |
| Buy | 17 | 70.8% |
| Hold | 4 | 16.7% |
| Sell | 0 | 0.0% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 24
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus rises 8.5% and revenue estimates rise 7.7%.
- Fiscal year ending Dec 31, 2026
- $8.59
- EPS consensus, revenue $26.26B
- Fiscal year ending Dec 31, 2027
- $9.32
- EPS consensus, revenue $28.28B
- Next report
- Jan 26, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $8.59 | $8.58 to $8.62 | 24 | $26.26B | $26.19B to $26.31B | 22 |
| Dec 31, 2027 | $9.32 | $9.17 to $9.49 | 24 | $28.28B | $27.65B to $28.89B | 22 |
Quarterly Estimates
The EPS consensus falls from $2.50 for the quarter ending Dec 31, 2026 to $2.24 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | $2.50 | $2.42 to $2.63 | 23 | $7.57B | $7.27B to $7.92B | 22 |
| Mar 31, 2027 | $2.24 | $2.15 to $2.28 | 13 | $6.63B | $6.50B to $6.73B | 10 |
Estimate Revisions
Across the 3 periods below, the last 30 days brought 45 upward and 11 downward EPS revisions. Raises outnumber cuts in every period.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Dec 31, 2026 | 23 | 0 |
| Fiscal year ending Dec 31, 2027 | 15 | 7 |
| Quarter ending Mar 31, 2027 | 7 | 4 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Dec 31, 2026 has risen 0.9% from $8.51.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Dec 31, 2026 | $8.59 | $8.59 | $8.51 | $8.51 | $8.51 | +1.0% |
| Fiscal year ending Dec 31, 2027 | $9.32 | $9.32 | $9.30 | $9.30 | $9.30 | +0.2% |
| Quarter ending Mar 31, 2027 | $2.24 | $2.24 | $2.24 | $2.24 | $2.23 | +0.3% |
Frequently Asked Questions About DHR
What is the DHR stock forecast?
Consensus analyst estimates put Danaher's EPS at $8.59 for the fiscal year ending Dec 31, 2026, on revenue of $26.26B. The consensus rating from 24 analysts is Buy.
How do analysts rate DHR stock?
Of 24 analysts covering Danaher, 3 rate it Strong Buy, 17 Buy, 4 Hold, 0 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from DHR next year?
For the fiscal year ending Dec 31, 2026, the consensus EPS estimate is $8.59, with estimates from $8.58 to $8.62 from 24 analysts. For the fiscal year ending Dec 31, 2027, the consensus EPS estimate is $9.32, with estimates from $9.17 to $9.49 from 24 analysts.
What revenue do analysts expect from Danaher next year?
For the fiscal year ending Dec 31, 2026, the consensus revenue estimate is $26.26B, with estimates from $26.19B to $26.31B. For the fiscal year ending Dec 31, 2027, the consensus revenue estimate is $28.28B, with estimates from $27.65B to $28.89B.
How many analysts cover DHR?
24 analysts rate Danaher stock, and 24 analysts estimate its EPS for the fiscal year ending Dec 31, 2026.
DHR pages: Overview, Dividends, Earnings, Forecast, Financials, Valuation, Competitors, Government Contracts